MGNX Quote, Financials, Valuation and Earnings

Dare Bioscience has a net margin of -311.07% compared to Macrogenics's net margin of -17219.13%. Macrogenics's return on equity of -58.23% beat Dare Bioscience's return on equity of --.

Macrogenics has a consensus price target of $4.20, signalling upside risk potential of 176.32%. On the other hand Dare Bioscience has an analysts' consensus of $13.00 which suggests that it could grow by 396.18%. Given that Dare Bioscience has higher upside potential than Macrogenics, analysts believe Dare Bioscience is more attractive than Macrogenics.

Macrogenics has a beta of 1.587, which suggesting that the stock is 58.67% more volatile than S&P 500. In comparison Dare Bioscience has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.754%.

Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dare Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. Dare Bioscience pays out -- of its earnings as a dividend.

Macrogenics quarterly revenues are $13.2M, which are larger than Dare Bioscience quarterly revenues of $25.4K. Macrogenics's net income of -$41M is lower than Dare Bioscience's net income of -$4.4M. Notably, Macrogenics's price-to-earnings ratio is -- while Dare Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.63x versus 854.30x for Dare Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Moleculin Biotech has a net margin of -311.07% compared to Macrogenics's net margin of --. Macrogenics's return on equity of -58.23% beat Moleculin Biotech's return on equity of --.

Macrogenics has a consensus price target of $4.20, signalling upside risk potential of 176.32%. On the other hand Moleculin Biotech has an analysts' consensus of $7.00 which suggests that it could grow by 993.75%. Given that Moleculin Biotech has higher upside potential than Macrogenics, analysts believe Moleculin Biotech is more attractive than Macrogenics.

Macrogenics has a beta of 1.587, which suggesting that the stock is 58.67% more volatile than S&P 500. In comparison Moleculin Biotech has a beta of 1.381, suggesting its more volatile than the S&P 500 by 38.119%.

Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moleculin Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. Moleculin Biotech pays out -- of its earnings as a dividend.

Macrogenics quarterly revenues are $13.2M, which are larger than Moleculin Biotech quarterly revenues of --. Macrogenics's net income of -$41M is lower than Moleculin Biotech's net income of -$6.4M. Notably, Macrogenics's price-to-earnings ratio is -- while Moleculin Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.63x versus -- for Moleculin Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -311.07% compared to Macrogenics's net margin of 6.22%. Macrogenics's return on equity of -58.23% beat Insulet's return on equity of 36.9%.

Macrogenics has a consensus price target of $4.20, signalling upside risk potential of 176.32%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 16.85%. Given that Macrogenics has higher upside potential than Insulet, analysts believe Macrogenics is more attractive than Insulet.

Macrogenics has a beta of 1.587, which suggesting that the stock is 58.67% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Macrogenics quarterly revenues are $13.2M, which are smaller than Insulet quarterly revenues of $569M. Macrogenics's net income of -$41M is lower than Insulet's net income of $35.4M. Notably, Macrogenics's price-to-earnings ratio is -- while Insulet's PE ratio is 51.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.63x versus 9.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -311.07% compared to Macrogenics's net margin of -15.19%. Macrogenics's return on equity of -58.23% beat Zevra Therapeutics's return on equity of -198.46%.

Macrogenics has a consensus price target of $4.20, signalling upside risk potential of 176.32%. On the other hand Zevra Therapeutics has an analysts' consensus of $22.75 which suggests that it could grow by 84.66%. Given that Macrogenics has higher upside potential than Zevra Therapeutics, analysts believe Macrogenics is more attractive than Zevra Therapeutics.

Macrogenics has a beta of 1.587, which suggesting that the stock is 58.67% more volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.965, suggesting its more volatile than the S&P 500 by 96.525%.

Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Macrogenics quarterly revenues are $13.2M, which are smaller than Zevra Therapeutics quarterly revenues of $20.4M. Macrogenics's net income of -$41M is lower than Zevra Therapeutics's net income of -$3.1M. Notably, Macrogenics's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.63x versus 14.97x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.